March 19, 2024

Partnering for Innovation in Life Sciences: Navigating the Digital Therapeutics (DTx) Landscape

A leading pharmaceutical company specialising in neurological treatments sought to enhance its portfolio with digital therapeutics (DTx), and approached m360 Research for competitive intelligence to identify a partner with innovative digital solutions to complement its pharmacotherapy offerings.


Navigating the DTx landscape presents several challenges. The market is fragmented, with numerous companies offering various digital solutions. Regulatory complexities, including evolving standards and regional variations, add another layer of difficulty.

m360 Research Solution

By leveraging its expertise in secondary research and deep understanding of the life sciences industry, m360 Research conducted a thorough analysis of the DTx landscape. This involved identifying key players, their products, market positioning, and potential synergies with the client’s portfolio. Our expert team applied a multi-stage selection process, initially screening a large number of companies, narrowing down based on specific criteria, and finally selecting the best-fit candidates.

In the initial search, m360 Research identified 60+ digital products designed to treat conditions affecting the central nervous system (CNS), including neurodegenerative disorders, psychiatric disorders, and other neurological conditions. These products were either digital therapies or prescription digital therapeutics (PDTs). While related, they have crucial differences:

Digital Therapy / Apps
Not Regulated
Many digital therapies and health apps are not regulated as medical devices and may not undergo the same level of scrutiny as PDTs

Not necessarily prescribed

They can be used by individuals without the need for a prescription

Evidence may vary

The level of evidence supporting their effectiveness can vary widely, from well-researched interventions to those with limited or no scientific backing
PDTs are regulated by the FDA or other regulatory bodies as medical devices, meaning they must meet specific standards for safety and efficacy
Used under supervision
They are typically used under the supervision of healthcare providers, who prescribe them to patients based on their medical needs
Supported by clinical evidence
PDTs are backed by clinical evidence demonstrating their effectiveness for specific medical conditions
All available information was analysed in detail, including indication, purpose, platform, safety, and efficacy data. m360 Research narrowed down the list to 15+ companies, which were included in a detailed report covering the most promising ones. The report included in-depth analysis of each company’s products, market positioning, potential synergies with the client, and recommendations for partnership.
After conducting a thorough search and analysis, m360 Research identified that a prescription digital therapeutic (PDT) company would be the best fit for our client, rather than a traditional digital therapy. The use of a PDT is expected to lead to better acceptance by physicians, easier integration into existing workflows, greater acceptance by payers, and the availability of high-quality data to support its potential.
Client Impact
Based on m360 Research’s recommendation, the client’s decision to partner with a prescription digital therapeutic (PDT) company had a transformative impact on their neurological treatment portfolio. By integrating PDTs with their pharmacotherapy offerings, the client was positioned to enhance patient outcomes through innovative digital solutions. This strategic move not only strengthened the client’s market competitiveness, but also demonstrated their commitment to pioneering advancements in neurological treatments.

Partner With Us

If you’ve been searching for solid partnerships to drive innovation, then look no further.

Latest Articles